Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 94


The molecular characterization and clinical management of multiple myeloma in the post-genome era.

Zhou Y, Barlogie B, Shaughnessy JD Jr.

Leukemia. 2009 Nov;23(11):1941-56. doi: 10.1038/leu.2009.160. Epub 2009 Aug 6. Review.


The use of molecular-based risk stratification and pharmacogenomics for outcome prediction and personalized therapeutic management of multiple myeloma.

Johnson SK, Heuck CJ, Albino AP, Qu P, Zhang Q, Barlogie B, Shaughnessy JD Jr.

Int J Hematol. 2011 Oct;94(4):321-33. doi: 10.1007/s12185-011-0948-y. Epub 2011 Oct 15. Review.


Gene expression profiling in multiple myeloma--reporting of entities, risk, and targets in clinical routine.

Meissner T, Seckinger A, Rème T, Hielscher T, Möhler T, Neben K, Goldschmidt H, Klein B, Hose D.

Clin Cancer Res. 2011 Dec 1;17(23):7240-7. doi: 10.1158/1078-0432.CCR-11-1628. Epub 2011 Oct 10.


The prognostic significance of cytogenetics and molecular profiling in multiple myeloma.

Sawyer JR.

Cancer Genet. 2011 Jan;204(1):3-12. doi: 10.1016/j.cancergencyto.2010.11.002. Review.


Gene expression risk signatures maintain prognostic power in multiple myeloma despite microarray probe set translation.

Hermansen NE, Borup R, Andersen MK, Vangsted AJ, Clausen NT, Kristensen DL, Nielsen FC, Gimsing P.

Int J Lab Hematol. 2016 Jun;38(3):298-307. doi: 10.1111/ijlh.12486. Epub 2016 Mar 29.


The shaping and functional consequences of the dosage effect landscape in multiple myeloma.

Samur MK, Shah PK, Wang X, Minvielle S, Magrangeas F, Avet-Loiseau H, Munshi NC, Li C.

BMC Genomics. 2013 Oct 2;14:672. doi: 10.1186/1471-2164-14-672.


Tumor cell gene expression changes following short-term in vivo exposure to single agent chemotherapeutics are related to survival in multiple myeloma.

Burington B, Barlogie B, Zhan F, Crowley J, Shaughnessy JD Jr.

Clin Cancer Res. 2008 Aug 1;14(15):4821-9. doi: 10.1158/1078-0432.CCR-07-4568.


Insights from the gene expression profiling of multiple myeloma.

Claudio JO, Masih-Khan E, Stewart AK.

Curr Hematol Rep. 2004 Jan;3(1):67-73. Review.


A gene expression based predictor for high risk myeloma treated with intensive therapy and autologous stem cell rescue.

Wu P, Walker BA, Broyl A, Kaiser M, Johnson DC, Kuiper R, van Duin M, Gregory WM, Davies FE, Brewer D, Hose D, Sonneveld P, Morgan GJ.

Leuk Lymphoma. 2015 Mar;56(3):594-601. doi: 10.3109/10428194.2014.911863. Epub 2014 Aug 19.


Gene signature combinations improve prognostic stratification of multiple myeloma patients.

Chng WJ, Chung TH, Kumar S, Usmani S, Munshi N, Avet-Loiseau H, Goldschmidt H, Durie B, Sonneveld P.

Leukemia. 2016 May;30(5):1071-8. doi: 10.1038/leu.2015.341. Epub 2015 Dec 16.


Gene expression profiling and multiple myeloma.

Shaughnessy J Jr, Zhan F, Barlogie B, Stewart AK.

Best Pract Res Clin Haematol. 2005;18(4):537-52. Review.


Superior results of Total Therapy 3 (2003-33) in gene expression profiling-defined low-risk multiple myeloma confirmed in subsequent trial 2006-66 with VRD maintenance.

Nair B, van Rhee F, Shaughnessy JD Jr, Anaissie E, Szymonifka J, Hoering A, Alsayed Y, Waheed S, Crowley J, Barlogie B.

Blood. 2010 May 27;115(21):4168-73. doi: 10.1182/blood-2009-11-255620. Epub 2010 Feb 2.


High-resolution genomic profiles define distinct clinico-pathogenetic subgroups of multiple myeloma patients.

Carrasco DR, Tonon G, Huang Y, Zhang Y, Sinha R, Feng B, Stewart JP, Zhan F, Khatry D, Protopopova M, Protopopov A, Sukhdeo K, Hanamura I, Stephens O, Barlogie B, Anderson KC, Chin L, Shaughnessy JD Jr, Brennan C, Depinho RA.

Cancer Cell. 2006 Apr;9(4):313-25.


Individualized therapy in multiple myeloma: are we there?

Girnius S, Munshi NC.

Semin Oncol. 2013 Oct;40(5):567-76. doi: 10.1053/j.seminoncol.2013.08.001.


A novel measure of chromosome instability can account for prognostic difference in multiple myeloma.

Chung TH, Mulligan G, Fonseca R, Chng WJ.

PLoS One. 2013 Jun 20;8(6):e66361. doi: 10.1371/journal.pone.0066361. Print 2013.


The flow cytometry-defined light chain cytoplasmic immunoglobulin index and an associated 12-gene expression signature are independent prognostic factors in multiple myeloma.

Papanikolaou X, Alapat D, Rosenthal A, Stein C, Epstein J, Owens R, Yaccoby S, Johnson S, Bailey C, Heuck C, Tian E, Joiner A, van Rhee F, Khan R, Zangari M, Jethava Y, Waheed S, Davies F, Morgan G, Barlogie B.

Leukemia. 2015 Aug;29(8):1713-20. doi: 10.1038/leu.2015.65. Epub 2015 Mar 10.


Evaluating gene expression profiling by quantitative polymerase chain reaction to develop a clinically feasible test for outcome prediction in multiple myeloma.

Sarasquete ME, Martínez-López J, Chillón MC, Alcoceba M, Corchete LA, Paiva B, Puig N, Sebastián E, Jiménez C, Mateos MV, Oriol A, Rosiñol L, Palomera L, Teruel AI, González Y, Lahuerta JJ, Bladé J, Gutiérrez NC, Fernández-Redondo E, González M, San Miguel JF, García-Sanz R.

Br J Haematol. 2013 Oct;163(2):223-34. doi: 10.1111/bjh.12519. Epub 2013 Aug 16.


Translating a gene expression signature for multiple myeloma prognosis into a robust high-throughput assay for clinical use.

van Laar R, Flinchum R, Brown N, Ramsey J, Riccitelli S, Heuck C, Barlogie B, Shaughnessy JD Jr.

BMC Med Genomics. 2014 May 17;7:25. doi: 10.1186/1755-8794-7-25.


Cancer/testis genes in multiple myeloma: expression patterns and prognosis value determined by microarray analysis.

Condomines M, Hose D, Raynaud P, Hundemer M, De Vos J, Baudard M, Moehler T, Pantesco V, Moos M, Schved JF, Rossi JF, Rème T, Goldschmidt H, Klein B.

J Immunol. 2007 Mar 1;178(5):3307-15.


Molecular dissection of hyperdiploid multiple myeloma by gene expression profiling.

Chng WJ, Kumar S, Vanwier S, Ahmann G, Price-Troska T, Henderson K, Chung TH, Kim S, Mulligan G, Bryant B, Carpten J, Gertz M, Rajkumar SV, Lacy M, Dispenzieri A, Kyle R, Greipp P, Bergsagel PL, Fonseca R.

Cancer Res. 2007 Apr 1;67(7):2982-9.

Supplemental Content

Support Center